Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$124.47 USD

124.47
207,836

-1.39 (-1.10%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $124.43 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

4 Medical Device Stocks to Top Q3 Earnings

A look at how medical device players are poised for this earnings season.

    Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

    Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.

      Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact

      Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.

        MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX

        Let's take a look at the major MedTech stocks within the broader medical community, slated to release their reports on Mar 1.

          Walgreens Teams Up with Fedex to Boost Retail Performance

          Walgreens Boots Alliance, Inc. (WBA) recently inked a multi-year partnership agreement with global express delivery services company FedEx Corporation (FDX).

            Align Poised On Global Expansion & Invisalign Teen Growth

            On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).

              Illumina (ILMN) Launches NovaSeq Series for $100 Genome

              Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.

                QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite

                QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.

                  LLabCorp: Reimbursement Scenario a Drag Amid Other Woes

                  On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.

                    ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders

                    ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.

                      Myriad Genetics: Evidence Street Reviews EndoPredict Test

                      Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.

                        Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View

                        Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.

                          Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite

                          Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.

                            Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging

                            Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.

                              ResMed Achieves Key Milestone in Sleep-Disordered Breathing

                              After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.

                                4 Medical Device Stocks on a Bull Run this Earnings Season

                                The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.